Years after the peak of the COVID-19 pandemic, healthcare systems in countries such as the United Kingdom, Italy, the United States and Germany continue to confront the enduring impact of what is now widely referred to as Long COVID. This condition, characterised by persistent symptoms lasting weeks or months beyond the acute phase of infection, has emerged as a complex and multifaceted public health challenge.
Clinical data indicate that Long COVID affects a significant proportion of individuals, regardless of the severity of their initial illness. Common symptoms include chronic fatigue, dyspnoea, cognitive impairment—often described as “brain fog”—and cardiovascular irregularities. In some cases, patients report symptoms persisting for over a year, significantly affecting quality of life and the ability to return to normal activities.
In the United Kingdom, specialised Long COVID clinics have been established within the National Health Service (NHS), providing multidisciplinary care that includes respiratory therapy, neurological assessment and psychological support. Italy has similarly invested in post-COVID care programmes, with researchers investigating the role of persistent inflammation and immune dysregulation.
In the United States, large-scale research initiatives funded by federal agencies aim to better understand the biological mechanisms underlying the condition. Early hypotheses suggest that viral persistence, autoimmune responses and microvascular damage may all contribute to symptom development.
Despite ongoing research, treatment remains largely symptomatic, with no universally accepted therapeutic protocol. This has led to calls for increased international collaboration and funding to address what many experts consider the next major phase of the pandemic’s health impact.